DMK

DMK Pharmaceuticals Corporation Common Stock
DMK
Market cap $2.34M

Delisted

DMK was delisted on the 6th of February, 2024.

Back to rankings

About: DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Employees: 12

Healthcare Drug Manufacturers - General

Financial journalist opinion

DMK Pharmaceuticals Commences Restructuring Proceeding

San Diego, California--(Newsfile Corp. - February 2, 2024) - DMK Pharmaceuticals Corporation (NASDAQ: DMK) ("DMK" or the "Company"), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, and certain of its direct and indirect subsidiaries (collectively, the "Company Parties") today (the "Petition Date") commenced bankruptcy cases (the "Chapter 11 Cases") by filing voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On the Petition Date, the Company Parties filed a motion with the Bankruptcy Court seeking to jointly administer the Chapter 11 Cases under the caption "In re: DMK Pharmaceuticals Corporation, et al.

DMK Pharmaceuticals Commences Restructuring Proceeding

DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI

Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generation Company seeking commercialization partnerships in the United States, Canada, and Europe to expand revenue generation

DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI

DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced that it is reacquiring the rights to its SYMJEPI® (epinephrine) Injection 0.3mg and SYMJEPI® (epinephrine) Injection 0.15mg products from USWM, LLC (“USWM” or “US WorldMeds”). US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI® and ZIMHI® (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts.

DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update

DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI ® and thus increase shareholder value

DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™